- Patient characteristics are consistent with other DLB studies -
View original post here:
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
PDUFA target action date set for December 20, 2024 PDUFA target action date set for December 20, 2024
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended on 30 September 2024. The full report can be viewed here.
Original post:
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET
Read the original post:
Orion Corporation: Managers’ transactions – Henrik Stenqvist
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million;
Excerpt from:
Biodesix Announces Third Quarter 2024 Results and Highlights
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
View original post here:
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug.
Read more from the original source:
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant...
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.
Read the rest here:
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET.
Read this article:
Skye Bioscience to Announce Third Quarter 2024 Results